China-based pharmaceutical company Lynk Pharmaceuticals has successfully raised $44m in a second tranche of Series C funding.
This takes the overall size of the round to CNY 322m (USD 44m). The funding was led by New Alliance Capital and Lilly Asia Ventures, with participation from other investors.
Lynk Pharmaceuticals is a drug developer that focuses on improving the quality of life for patients with serious illnesses. The company has developed a range of innovative products that have been successful in treating a variety of diseases. The latest funding will be used to expand the company’s research and development efforts, as well as to support its ongoing clinical trials.
This latest funding round is a testament to the growing interest in China’s tech and healthcare sectors. With the country’s rapidly expanding middle class and increasing demand for high-quality medical care, there is significant potential for growth in these industries.
As such, Lynk Pharmaceuticals is well-positioned to take advantage of this trend and continue to expand its operations in the years to come.
China’s Lynk’s Series C Funding
Overview of the Increase to $44m
China-based Lynk Pharmaceuticals has increased its Series C round funding to $44m, following a successful funding round.
The company raised $22m in its initial Series C1 funding round in May 2023, and then raised an additional $22m in its Series C2 funding round in September 2023, bringing the total amount raised in the round to $44m.
The funding will be used to accelerate the clinical development of Lynk’s core products, which are focused on the treatment of cancer and other serious diseases.
The company is currently conducting clinical trials for its lead product, a novel cancer drug, and plans to use the funding to expand its clinical development program and bring its products to market more quickly.
Lynk Pharmaceuticals is a clinical-stage company that was founded in 2015.
The company is focused on developing innovative therapies for the treatment of cancer and other serious diseases. The company’s lead product is a novel cancer drug that has shown promising results in early clinical trials.
The increase in Lynk’s Series C funding is a testament to the company’s strong growth potential and the confidence that investors have in its management team and product pipeline.
With the additional funding, Lynk is well-positioned to continue its clinical development program and bring its innovative therapies to patients in need.
Investors and Private Equity Activity
Lynk Pharmaceutical has recently increased its Series C funding to $44m, with Tiger Global leading the round. This development is indicative of the growing interest in China’s pharmaceutical industry, which has been attracting private equity investors in recent years.
Role of Tiger Global
Tiger Global has been an active investor in China’s private equity market, with a particular focus on technology and healthcare companies. The firm’s investment in Lynk Pharmaceutical is in line with its strategy of backing companies with innovative products and strong growth potential.
Tiger Global’s investment in Lynk Pharmaceutical is also a reflection of the increasing interest in China’s healthcare sector, which has been driven by rising demand for high-quality medical services. With China’s ageing population and growing middle class, healthcare is expected to be a key growth area in the coming years.
Overall, Lynk Pharmaceutical’s successful fundraising round highlights the growing interest in China’s healthcare sector, and the potential for private equity investors to generate strong returns by backing innovative companies with strong growth potential.
Previous Funding Rounds
Lynk Pharmaceuticals has successfully raised funding in the past to support its growth and development. The company has completed two funding rounds before the current Series C round.
Series A Round
In 2017, Lynk Pharmaceuticals raised CNY 50 million (USD 7.4 million) in its Series A funding round. The round was led by Legend Capital and was participated by Qianhai FOF Fund and other investors. The funds were used to support the company’s research and development efforts, as well as to expand its team.
Series B Round
In 2019, Lynk Pharmaceuticals raised CNY 200 million (USD 29.4 million) in its Series B funding round. The round was led by Qianhai FOF Fund and was participated by Legend Capital, Lilly Asia Ventures, and New Alliance Capital. The funds were used to support the company’s clinical trials and to advance its pipeline of innovative drug candidates.
Overall, Lynk Pharmaceuticals has raised a total of CNY 572 million (USD 84.1 million) in funding to date, including the current Series C round. The company’s successful fundraising efforts reflect the confidence of investors in its innovative drug development programs and its potential for growth and success in the pharmaceutical industry.
Lynk’s Product and Platform
Lynk Pharmaceuticals is a clinical-stage company that focuses on developing innovative drugs for unmet medical needs. The company’s product pipeline includes several drugs in various stages of development, targeting different diseases such as cancer, autoimmune disorders, and infectious diseases.
Lynk’s lead product candidate is LYNK-010, a monoclonal antibody designed to treat certain types of solid tumors. The drug has shown promising results in preclinical studies and is currently in Phase I clinical trials.
Apart from its product pipeline, Lynk also offers a platform that connects patients with clinical trials. The platform allows patients to search for clinical trials based on their medical condition, location, and other criteria. The platform also provides information about the trials, including eligibility criteria, trial design, and expected outcomes.
Lynk’s platform is designed to make it easier for patients to find and participate in clinical trials. By connecting patients with clinical trials, Lynk aims to accelerate the development of new drugs and improve patient outcomes.
Overall, Lynk’s product pipeline and platform demonstrate the company’s commitment to developing innovative drugs and improving patient outcomes. With the recent increase in funding, Lynk is well-positioned to continue its efforts in developing new drugs and expanding its platform to reach more patients.
